Skip to content

Circles

T

TScan Therapeutics, Inc.

TCRX· Nasdaq

T

TCRXTScan Therapeutics, Inc.

TCRXTScan Therapeutics, Inc.·Earnings record

Q3 2020

Source filing unavailable

Previous · Q2 2020 Next · Q4 2020

Q3 2020 · —

Revenue

$290.00K

no prior Q3 2019 on file

Net Income

-$7.17M

no prior Q3 2019 on file

EPS Diluted

-$7.16

no prior Q3 2019 on file

Operating Income-$7,171,000—

Operating Cash Flowderived-$5,789,000—

Same quarter

no prior Q3 2019 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Filing lag

Quarterly history

Q2 ’20Q3 ’20Q4 ’20^d Q1 ’21 Q2 ’21 Q3 ’21 Q4 ’21^d Q1 ’22 Q2 ’22…

TScan Therapeutics, Inc. · CIK 1783328 · Engraved from SEC EDGAR

Free Cash Flowderived

-$7,132,000—

Margins · derived

Operating margin-2472.8%

Net margin-2472.4%

Thaler ResearchEngraved from SEC EDGAR© 2026 Thaler. All rights reserved.Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Platform

Using AI API SDKs CLI

Research

News Listen Earnings Insiders Holders Compare Metrics

Screener Watchlists Pies Notes Your companies

Learn

Thaler

Thaler Agent Promise Provenance Circles Account Terms Privacy